Skip to main content
Home

Main navigation

  • Centers & Programs
    • Centers
      • Center for Energy Studies
      • Center for Health and Biosciences
      • Center for the Middle East
      • Center for Public Finance
      • Center for the U.S. and Mexico
      • McNair Center
      Center for Energy Studies
      Providing new insights on the role of economics, policy and regulation in the performance and evolution of energy markets.
      More Details
      The globe at night, lights in populated areas illuminated
      Center for Health and Biosciences
      Advancing data-based policies that promote health and well-being in the U.S. and around the world.
      More Details
      Female healthcare worker lifts finger to press digital buttons featuring topical iconography
      Edward P. Djerejian Center for the Middle East
      Developing pragmatic policy approaches to the region’s enduring political, economic and societal concerns.
      More Details
      Topographic map of Middle East
      Center for Public Finance
      Delivering research and analysis on the effects of major U.S. fiscal policies.
      More Details
      Stack of coins with mathematical figure overlays
      Center for the U.S. and Mexico
      Strengthening the binational relationship by addressing major concerns on both sides of the border.
      More Details
      Textured flags of America and Mexico
      McNair Center for Entrepreneurship and Economic Growth
      Providing actionable policy analysis and recommendations that aim to expand the economy through private enterprise.
      More Details
      Professionals gather around a large table with laptops, printed documents and coffee cups for a business meeting
    • Programs
      • China Studies
      • Drug Policy
      • International Economics
      • Presidential Elections
      • Religion & Public Policy
      • Science & Technology Policy
      • Space Policy
      China Studies
      Analyzing the influence of the transnational circulation of people, technologies, commodities and ideas in China.
      Read More
      Person walks alongside large banner with Chinese characters
      Drug Policy
      Pursuing research and open debate to develop pragmatic drug policies based on common sense and driven by human rights interests.
      Read More
      Marijuana
      International Economics
      Studying timely issues in global economic policy as well as developmental policy in foreign countries.
      Read More
      International paper currencies stacked together, showing range of colors and styles
      Presidential Elections
      Offering nonpartisan analysis of elections to better understand the changing dynamics of presidential campaigns.
      Read More
      An assortment of campaign buttons from a variety of US elections and political pursuits are displayed in a collage
      Religion and Public Policy
      Exploring how religion and cultural factors interact with public policy issues.
      Read More
      A worn path stretches between rows of olive trees
      Science and Technology Policy
      Addressing a broad range of policy issues that affect scientists and their research.
      Read More
      A scientist picks up test tubes from a rack.
      Space Policy
      Focusing on U.S. space policy and the future of space travel.
      Read More
      The International Space Station (ISS) orbits the Earth at sunrise
  • Events
    The front of Baker Hall, from across the plaza, with fountain in foreground
    Center for Health and Biosciences | Roundtable
    Tue, Feb. 07, 2023 | 4:30 pm - 5:30 pm
    Baker Briefing: Addressing the Maternal Mortality Crisis in Texas See Details
    Child at border plays in the dirt with superhero toy
    Center for the U.S. and Mexico
    Thu, Feb. 23, 2023 | 5 pm - 7:30 pm
    Immigration Reform and the Impact on Children: A Town Hall Discussion See Details
    Tile mosaic over an entrance to Baker Hall that reads "A Bridge Between the World of Ideas and the World of Action"
    Center for the U.S. and Mexico | Edward P. Djerejian Center for the Middle East
    Wed, Mar. 15, 2023 | 5:30 pm - 7:30 pm
    Charting Paths Forward on Immigration Reform See Details
  • Experts
    • Biomedical Research
    • Child Health
    • China
    • Conflict Resolution in the Middle East
    • Domestic Health Policy
    • Drug Policy
    • Energy
    • Entrepreneurship and Economic Growth
    • Global Health
    • Health and Biosciences
    • Human Rights and Refugees
    • International Economics
    • Islam and Politics
    • Latin American Energy
    • Middle East
    • Political Economy of the Arab Gulf
    • Presidential Elections
    • Public Finance
    • Religion and Public Policy
    • Science and Technology
    • Space Policy
    • Texas Politics
    • U.S. and Iran
    • U.S. and Mexico
    • See All Experts
    • Experts in the News
  • Support
    • Join the Baker Roundtable
      Join the Baker Roundtable
      Learn more about the Baker Institute’s membership forum, which supports the mission of the institute and offers members exclusive access to experts and events.
      Read More
      RT
    • Major Gifts
      Major Gifts
      Major gifts provide the funds necessary for the Baker Institute to explore new areas of study and research, and expand current programs.
      Read More
      Wallace S. Wilson meeting with former British Prime Minister Tony Blair
    • Endowments
      Endowments
      Endowment gifts provide the Baker Institute with permanent resources that support research programs, fellows and scholars.
      Read More
      Pictured from left are William Martin, Katharine Neill Harris, Ambassador Edward Djerejian, Alfred C. Glassell, III, and Pam Lindberg
    • Planned Giving
      Planned Giving

      Plan a gift that will ensure lasting, meaningful support for policy programs important to you.

       

      Read More
      meeting
    • Corporate Support
      Corporate Support
      Corporations can become involved with the institute in a number of ways and see the benefit from the research conducted by our fellows and scholars.
      Read More
      Wide shot of the Doré Commons during a Shell Distinguished Lecture Series event featuring Wim Thomas
  • About
    • People
      People
      Learn more about the Baker Institute's leadership and get contact information for the administrative staff.
      Read More
      Secretary James A. Baker, III, stands with a portion of the Berlin Wall, outside of Baker Hall
    • Student Opportunities
      Student Opportunities
      Through the internships on campus and beyond, Rice students can explore careers in public policy, or simply become better informed about important issues of the day.
      Read More
      Amb. Edward P. Djerejian speaks with students outside Baker Hall
    • Annual Report
    • Blog
    • Contact
      Contact Us
      Complete a form for event, media or other inquiries, and get directions and parking information for the Baker Institute.
      Read More
      The front of Baker Hall, from across the plaza, with fountain in foreground
  • Contact
  • Research
    • Economics & Finance
      Economics & Finance
      Read More
    • Energy
      Latest Energy Research
      Summary on Latest Energy Research
      Read More
    • Foreign Policy
      Foreign Policy
      Read More
    • Domestic Policy
      Domestic Policy
      Read More
    • Health & Science
      Health & Science
      Read More
    • All Publications
  • Facebook
  • Youtube
  • Twitter
  • Linkedin
  • Economics & Finance
  • Energy
  • Foreign Policy
  • Domestic Policy
  • Health & Science
  • All Publications
Center for Health and Biosciences | Domestic Health Policy Analysis | Commentary

How Mark Cuban's Prescription Drug Disruption Could Save Lives

November 29, 2022 | Hagop M. Kantarjian
RX Medicine

Table of Contents

Author(s)

Headshot of Hagop Kantarjian
Hagop M. Kantarjian
Nonresident Fellow in Health Policy
Read More

Share this Publication

  • Facebook
  • Twitter
  • Email
  • Linkedin
  • Print This Publication

The development of highly selective and effective treatments that target the cause of chronic myeloid leukemia (CML) was nothing short of a therapeutic miracle. Introduced into standard therapy in 2000, they changed CML from a fatal disease to a chronic condition compatible with normal life.

Today, several such oral drugs are available on the market. But they cost, on average, more than $200,000 per year when under patent — which can be for 12 to 20 years or longer, depending on how the pharmaceutical company modifies the patent's conditions. With many insurers charging patients out-of-pocket expenses of up to 25%, such drugs — though readily available — can become unaffordable without an annual cap, making patients “functionally uninsured.” It is estimated that up to 30% of patients with CML and other cancers are in this situation.

The first such drug for CML was imatinib (Gleevec). It lost its patent in 2017 and is now available as a generic drug, with 15 formulations on the market in the U.S. The common wisdom is that once four to five generic versions of a drug become available, its price falls drastically. Sadly, this has not been the case for CML drugs, nor for most cancer drugs in the existing health care system.

It is true that the average price of the 15 imatinib generics has fallen from more than $130,000 per year to about $5,000 per year (a price still much higher than the cost to manufacture the drug, which is less than $400 per year). But that is the price drug companies charge. Once a drug is manufactured, it starts a complex, often inconsistent supply chain path, allowing different intermediaries along the way to insert their own profit margins.

These include wholesalers, pharmacies and hospitals, group purchasing organizations and pharmacy benefit managers. The price that wholesalers (including the top three U.S. drug distributors, AmerisourceBergen, McKesson and Cardinal Health) pay to acquire drugs from manufacturers is called a wholesale acquisition cost, or WAC, while the price that pharmacies or hospitals pay wholesalers is known as the average wholesale price, or AWP. Pharmacies and hospitals are usually part of a group purchasing organization that negotiates to buy drugs at a lower cost, called the GPO price. As the supply chain moves closer to the patient, other intermediaries become involved, including pharmacy benefit managers, who control what medications are on insurance formularies. The pharmacy benefit managers negotiate drug prices directly with manufacturers and often maximize their leverage by securing deals with manufacturers for significant rebates. This increases both the profits of pharmacy benefit managers and the prices patients pay.

The end result is a price bubble that benefits many of the players, but not the patient. In the instance of generic imatinib, while the average price of the drug when it leaves the manufacturer is $5,000 per year, 12 of the 15 generics end up costing the patient the same price — an astounding $132,000 per year. 

Enter into this mix billionaire Mark Cuban, who recently launched Cost Plus, an online drug company that bypasses distributors and offers generic medications to patients (with a physician prescription) at cost plus 15%. The company’s mission is to reduce the complexity of the drug supply chain and charge the lowest possible prices while still making good profits. Among the list of available drugs is generic imatinib, offered at $47 per month. Purchased through this process, the price can now be as low as $565 per year, which is relatively affordable and even cheaper than what a patient with prescription insurance might pay.

This is a model that physicians and patients should publicize, encourage and use often. Similar companies are following the same model, including Civica Rx, ScriptCo Pharmacy, Honeybee Pharmacy, GeniusRx, Ro Pharmacy and hopefully many others. Each has its variations but adheres to the common theme of bypassing intermediaries and providing the fastest and cheapest route for a drug from manufacturer to patient. A study in the Annals of Internal Medicine has estimated that Medicare could have saved, conservatively, $3.6 billion in 2020 had it purchased 77 generic drugs from Cuban’s Cost Plus Drug Company.

There are some downsides to this model, as evidenced by Cost Plus. First, most of the medications offered are generics and are only for chronic conditions. Second, patients with chronic conditions are often on multiple medications, and if they cannot obtain all their prescriptions through Cost Plus and need to use other pharmacies, their prescriptions will be fragmented. And third, Cost Plus does not bill insurance, and patients will not be contributing to their deductibles.

These issues will hopefully be mitigated over time as the success of this model over the traditional distribution path encourages Cost Plus and similar companies to expand their inventories and accept insurance. By disrupting the traditional U.S. drug supply chain, the “Mark Cuban effect” could significantly reduce the cost of drugs and health care in the U.S., in addition to making many much-needed cancer drugs available and affordable for more patients. This could save the lives of thousands of patients over the next decade.

It's an idea whose time has come.
 

This commentary originally appeared in the Dallas Morning News (subscription required).

  • Print This Publication
  • Share
    • Facebook
    • Twitter
    • Email
    • Linkedin

Related Research

Kidney imaging
Center for Health and Biosciences | Journal

Fifty Years of a National Program for the Treatment of Kidney Failure

Read More
Solider sitting in folding chair
Center for Health and Biosciences | Domestic Health Policy Analysis | Newsletter

Should Health Care Providers Ask Their Regular Patients About Their Sexual Health?

Read More
  • Facebook
  • Youtube
  • Twitter
  • Linkedin
  • Donate Now
  • Media Inquiries
  • Membership
  • About the Institute
  • Rice.edu
Contact Us

6100 Main Street
Baker Hall MS-40, Suite 120
Houston, TX 77005

Email: bipp@rice.edu
Phone: 713-348-4683
Fax: 713-348-5993

Baker Institute Newsletter

The email newsletter of Rice University's Baker Institute for Public Policy provides a snapshot of institute news, research and upcoming events.

Sign Up

  • © Rice University's Baker Institute for Public Policy
  • Web Accessibility
  • Privacy Policy